EXEL vs. HALO, RGEN, CRL, MEDP, NRC, NBIX, PCVX, RVMD, CRSP, and KRYS
Should you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Halozyme Therapeutics (HALO), Repligen (RGEN), Charles River Laboratories International (CRL), Medpace (MEDP), National Research (NRC), Neurocrine Biosciences (NBIX), Vaxcyte (PCVX), Revolution Medicines (RVMD), CRISPR Therapeutics (CRSP), and Krystal Biotech (KRYS).
Halozyme Therapeutics (NASDAQ:HALO) and Exelixis (NASDAQ:EXEL) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Halozyme Therapeutics has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 2.4% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 2.9% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Halozyme Therapeutics presently has a consensus price target of $53.29, suggesting a potential upside of 38.15%. Exelixis has a consensus price target of $26.29, suggesting a potential upside of 10.91%. Given Exelixis' stronger consensus rating and higher probable upside, analysts clearly believe Halozyme Therapeutics is more favorable than Exelixis.
Exelixis received 75 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.02% of users gave Halozyme Therapeutics an outperform vote while only 68.09% of users gave Exelixis an outperform vote.
In the previous week, Halozyme Therapeutics had 6 more articles in the media than Exelixis. MarketBeat recorded 18 mentions for Halozyme Therapeutics and 12 mentions for Exelixis. Exelixis' average media sentiment score of 0.82 beat Halozyme Therapeutics' score of 0.49 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Halozyme Therapeutics has a net margin of 33.96% compared to Halozyme Therapeutics' net margin of 11.35%. Exelixis' return on equity of 248.20% beat Halozyme Therapeutics' return on equity.
Halozyme Therapeutics has higher earnings, but lower revenue than Exelixis. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.
Summary
Halozyme Therapeutics beats Exelixis on 13 of the 18 factors compared between the two stocks.
Get Exelixis News Delivered to You Automatically
Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exelixis Competitors List
Related Companies and Tools
